1. Home
  2. VYNE

VYNE

VYNE Therapeutics Inc.

Logo VYNE Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-16-2024 3:31pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.

Founded: 2003 Country:
United States
United States
Employees: N/A City: BRIDGEWATER
Market Cap: 42.6M IPO Year: 2018
Target Price: $7.38 AVG Volume (30 days): 107.0K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.78 EPS Growth: N/A
52 Week Low/High: $1.67 - $8.73 Next Earning Date: 05-09-2024
Revenue: $424,000 Revenue Growth: -11.11%
Revenue Growth (this year): -3.77% Revenue Growth (next year): N/A

Share on Social Networks: